NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

On this news, the price of Iovance's shares fell 44.8%, from $1.42 per share to close at $1.75 per share on May 9, 2025, on unusually heavy trading volume. NEW YORK and NEW ORLEANS, May 20, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutic ...

Entering trading this week, shares of Iovance Biotherapeutics (IOVA 4.10%) have crashed by nearly 78% since the start of the year. It has been an abysmal start to 2025 for a company that does possess some attractive long-term growth prospects. But despite the optimism, a wave of bearishness has taken over, with Iovance's stock in the midst of a deep free fall. What's behind this sell-off, and can this be a good buying opportunity for long-term investors, or are you better off avoiding the stock? The company ...

NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between August 8, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/iovance-biotherapeutics-in ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=148839&from=4CLASS PERI ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between August 8, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/iovance-biotherapeut ...

诉讼案件概述 - 罗森律师事务所宣布代表在2024年5月9日至2025年5月8日期间购买Iovance Biotherapeutics证券的股东提起集体诉讼 [1] - 诉讼指控被告在集体诉讼期间作出虚假和误导性陈述或未披露关键信息 [4] 指控内容 - 新授权的治疗中心(ATCs)在开始使用Amtagvi治疗患者时面临更长时间延迟 [4] - Iovance销售团队和新ATCs在患者识别和选择方面效率低下导致患者流失率上升 [4] - 上述问题导致成本增加和收入下降因为ATCs无法跟上产品制造速度 [4] - 被告对Iovance业务运营和前景的积极陈述因此缺乏合理基础并具有重大误导性 [4] 诉讼参与方式 - 投资者可通过罗森律师事务所网站或联系Phillip Kim律师参与集体诉讼 [3][6] - 投资者需在2025年7月14日前向法院申请成为首席原告 [1][3] - 首席原告将代表其他集体成员指导诉讼 [3] 律师事务所背景 - 罗森律师事务所在证券集体诉讼领域具有丰富经验专注于投资者权益保护 [5] - 该律所曾创下针对中国公司的最大证券集体诉讼和解记录 [5] - 2017年被ISS证券集体诉讼服务评为和解数量第一律所2013年以来每年排名前四 [5] - 2019年为投资者追回超过4.38亿美元2020年创始合伙人被Law360评为原告律师界泰斗 [5]

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025. SO WHAT: If you purchased Iovance securities during the Cla ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, ...